Role of SIRT-3, p-mTOR and HIF-1α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin

Rapamycin improves insulin resistance and hepatic steatosis in type 2 diabetes rats through activation of autophagy

(2018) Wan Zhou et al.   CELL BIOLOGY INTERNATIONAL

Association of PD-L1 and HIF-1α Coexpression with Poor Prognosis in Hepatocellular Carcinoma

(2018) Xiaomeng Dai et al.   Translational Oncology

Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale

(2017) Andrea Casadei Gardini et al.   EUROPEAN JOURNAL OF CANCER

Insulin Resistance in Relation to Lipids and Inflammation in Type-2 Diabetic Patients and Non-Diabetic People

(2016) Ying-Mei Feng et al.   PLoS One

Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib

(2015) Andrea Casadei Gardini et al.   EXPERT OPINION ON PHARMACOTHERAPY

mTOR: a pharmacologic target for autophagy regulation

(2015) Young Chul Kim et al.   JOURNAL OF CLINICAL INVESTIGATION

Autophagy regulates insulin resistance following endoplasmic reticulum stress in diabetes

(2015) Ning Zhang et al.   JOURNAL OF PHYSIOLOGY AND BIOCHEMISTRY

Sirtuin 3 inhibits hepatocellular carcinoma growth through the glycogen synthase kinase-3β/BCL2-associated X protein-dependent apoptotic pathway

(2015) C-L Song et al.   ONCOGENE

Decreased mitochondrial SIRT3 expression is a potential molecular biomarker associated with poor outcome in breast cancer

(2014) Mohamed Mokhtar Desouki et al.   HUMAN PATHOLOGY

Berberine reverts hepatic mitochondrial dysfunction in high-fat fed rats: A possible role for SirT3 activation

(2013) João Soeiro Teodoro et al.   MITOCHONDRION

Prognostic Significance of HIF-1α Expression in Hepatocellular Carcinoma: A Meta-Analysis

(2013) Su-Su Zheng et al.   PLoS One

Sirt3 inhibits hepatocellular carcinoma cell growth through reducing Mdm2-mediated p53 degradation

(2012) Yuan-Yuan Zhang et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

SIRT3 and cancer: Tumor promoter or suppressor?

(2011) Turki Y. Alhazzazi et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

The metabolic and toxicological considerations for mTOR inhibitors in the treatment of hepatocarcinoma

(2011) Francesca Ponziani et al.   Expert Opinion on Drug Metabolism & Toxicology

Sirt3 Promotes the Urea Cycle and Fatty Acid Oxidation during Dietary Restriction

(2011) William C. Hallows et al.   MOLECULAR CELL

SirT3 suppresses hypoxia inducible factor 1α and tumor growth by inhibiting mitochondrial ROS production

(2011) E L Bell et al.   ONCOGENE

Sirtuin-3 (SIRT3), a novel potential therapeutic target for oral cancer

(2010) Turki Y. Alhazzazi et al.   CANCER

SIRT3 Deacetylates Mitochondrial 3-Hydroxy-3-Methylglutaryl CoA Synthase 2 and Regulates Ketone Body Production

(2010) Tadahiro Shimazu et al.   Cell Metabolism

SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation

(2010) Matthew D. Hirschey et al.   NATURE

Hepatic Autophagy Is Suppressed in the Presence of Insulin Resistance and Hyperinsulinemia

(2009) Hui-Yu Liu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma

(2009) Ledu Zhou et al.   MEDICAL ONCOLOGY

Pivotal Role of mTOR Signaling in Hepatocellular Carcinoma

(2008) Augusto Villanueva et al.   GASTROENTEROLOGY